The US Food and Drug Administration (FDA) has approved Medicalgorithmics’ ECG wearable unit, Qpatch.

The new ECG wearable device has been designed to measure individual ECG signals and obtain accurate cardiac arrhythmia diagnoses from monitoring sessions of up to 15 days.

It features an eInk screen that allows physicians and patients to interact with the wearable.

Qpatch also provides real-time ECG readings that can be observed through near-field communication on a smartphone.

This allows ongoing quality control of the recorded ECG signal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Medicalgorithmics board member Jarosław Jerzakowski said: “Securing the FDA approval for Qpatch is a major milestone celebrating the intensive effort that we have put into this project.

“Thanks to Qpatch our offer is now comprehensive. ECG diagnostics using wearables is very popular in the US and a method desired by both physicians and users.

“The FDA approval is a green light for us to prepare Qpatch’s market entry in the United States. We also want to pursue foreign markets as quickly as possible in regions where we have already been developing our sales.”

The company stated that the new device is waterproof, can be used with standard inexpensive electrodes and has a low weight for convenience.

It also noted that the Qpatch ECG monitoring device has been selected for a clinical trial that will be conducted by leading research centres in the Cardiac Surgery Research Network (CTSN).

The National Institutes of Health (NIH) and National Heart, Lung and Blood Institute (NHLBI) will provide funds for the trial.